Promoting academic research in the field of health involves adding an economic and social dimension so that the knowledge and techniques acquired help to improve public health. This is one of the missions of Inserm.
What can be promoted?
- Promising research findings that could be the subject of patent protection. The objective is to license this patent to one or more partners in industry, whether existing or created for the purpose, or to enable the creation of a research collaboration with a view to possible future use.
- Technical information that could be the subject of a knowledge transfer, if this information is secret and well-identified.
- Research tools (animal models, cell models, antibodies, etc.) that could be promoted through material transfer agreements or licensing agreements, particularly when they are patent-protected.
- Software and databases that could be the subject of protection by the Agency for the Protection of Programs (APP) and exploited through licensing or specific partnerships.
- Research platforms and specific equipment that could be promoted through R&D collaborations or research service provision.
- Scientific expertise, regulated by legal provisions under the French Innovation Law.
At Inserm, there are also research projects and programs that are particularly concerned by promotion and the creation of public/private partnerships:
- Inserm’s cross-cutting scientific programs that incorporate fundamental, translational, technological and clinical research approaches in order to address major scientific challenges on topics such as aging, microbiota and the genomic variability of populations. These programs are open to academic and industrial partnerships, the objective being to accelerate the acquisition, transfer and promotion of knowledge, while potentially incorporating industry from the stage of the program’s conception.
- Technology Research Accelerators (ART) favor the development of disruptive technologies. The provision of technological innovations within Inserm’s laboratories will reinforce their potential for innovation and for the discovery of physiopathological mechanisms. The technologies developed thanks to ART are levers of innovation that encourage public-private partnerships.
- The Cohorts enable the creation of databases comprised of sets of subjects with certain characteristics in common who are monitored over time at the individual level in order to identify the onset of interesting health events. The establishment of public/multi-private partnerships make it possible to support these research subjects that are used over the long term.
It is never too soon to get in contact with the relevant structure.
Inventions/Patents: remember to complete an Invention disclosure form BEFORE publishing your results.
Download the form
The next steps
To find out more about the potential of your research in terms of promotion or about how to advance your promotion project, a number of initiatives exist at Inserm and in France.
Inserm Transfert is the completely private subsidiary of Inserm, under public service delegation, and specialized in technology transfer in the life and health sciences.
It assists Inserm research units in the promotion of their work: project sourcing, intellectual property, maturation, the search for and management of European funding, industrial partnerships, enterprise creation (start-ups), and more. Inserm Transfert has sector-specific experts at each stage of the innovation value chain.
One of its objectives is to set up long-term quality industrial partnerships, built on value, while allowing the possibility for as many innovations as possible.
Inserm Transfert is also targeted at industrial partners. It gives them access to innovations, know-how, expertise and the scientific excellence of the academic research performed at Inserm.
Its commercial offering is based on:
- the research tools and resources generated by Inserm laboratories;
- innovative and patented biomedical technologies;
- the creation of value from cohorts, databases, biobanks, etc.
It also offers industry the possibility to:
- form large-scale and tailor-made strategic R&D alliances;
- integrate clinical and public health research projects from their earliest stages;
- call on its expertise in the management of national, European and international projects.
The Technology Transfer Acceleration Companies (SATTs)
Originating from the Investments for the Future program, the SATTs can provide local assistance to start-ups, small and medium-sized enterprises, intermediate-sized enterprises and contribute to local economic development. What is more, they constitute a local partner for regional academic stakeholders. Inserm holds shares in six of these companies.
The SATTs define their own promotion strategy in line with academic and clinical site policy. They work in tandem with Inserm Transfert, which focuses mainly on Inserm’s strategic fields of innovation and national and international issues.
The complementary positioning of Inserm Transfert and the SATTs enable the technological maturation of any project.
Theme Valorization Consortium (CVT)
The Aviesan Theme Valorization Consortium (CVT) is a structure that coordinates the promotion actions of Aviesan members. It is run by pooling the strategic analysis potential of biology/health research stakeholders in strategic valorization fields (DVS)that have been identified beforehand.